Literature DB >> 20203491

Visceral versus somatic pain: similarities and differences.

Fernando Cervero1.   

Abstract

Inflammatory bowel disease and the irritable bowel syndrome are conditions characterized by chronic pain that generates persistent, hyperalgesic states in many regions of the body. It is difficult to explain the pain of conditions such as inflammatory bowel disease and irritable bowel syndrome by extrapolating directly from what is known about the mechanisms of somatic pain. Visceral and somatic pain show many differences not only in the psychophysics of the sensation, but also in the neurobiological mechanisms that mediate the sensory process. The activation and sensitization of visceral nociceptors are heavily influenced by the secretory and motor properties of the microenvironment where the sensory receptors are located. In some cases, epithelial cells can play a direct role in the activation of primary sensory neurons. Subclinical alterations of the epithelium can contribute to enhanced visceral sensitivity. Central hypersensitivity induced by visceral activation also shows differences with its somatic counterpart. Mobilization of AMPA receptors from the cytosol to the membrane of nociceptive neurons has been identified as a mechanism of sensitization of visceral pain pathways. Finally, functional pain syndromes, such as irritable bowel syndrome could be triggered or maintained by hormonal alterations, particularly those involving sex hormones such as estrogen. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20203491     DOI: 10.1159/000268115

Source DB:  PubMed          Journal:  Dig Dis        ISSN: 0257-2753            Impact factor:   2.404


  22 in total

Review 1.  [Perioperative pain management for abdominal and thoracic surgery].

Authors:  J S Englbrecht; E M Pogatzki-Zahn
Journal:  Schmerz       Date:  2014-06       Impact factor: 1.107

Review 2.  Stress and visceral pain: from animal models to clinical therapies.

Authors:  Muriel Larauche; Agata Mulak; Yvette Taché
Journal:  Exp Neurol       Date:  2011-05-06       Impact factor: 5.330

3.  sec-Butylpropylacetamide (SPD), a new amide derivative of valproic acid for the treatment of neuropathic and inflammatory pain.

Authors:  Dan Kaufmann; Peter J West; Misty D Smith; Boris Yagen; Meir Bialer; Marshall Devor; H Steve White; K C Brennan
Journal:  Pharmacol Res       Date:  2016-11-24       Impact factor: 7.658

Review 4.  [Pain is modality-specific : Differences in the perception and processing of interoceptive visceral compared to exteroceptive cutaneous heat pain stimuli].

Authors:  L R Koenen; S Elsenbruch
Journal:  Schmerz       Date:  2018-04       Impact factor: 1.107

Review 5.  Bloating and functional gastro-intestinal disorders: where are we and where are we going?

Authors:  Paola Iovino; Cristina Bucci; Fabrizio Tremolaterra; Antonella Santonicola; Giuseppe Chiarioni
Journal:  World J Gastroenterol       Date:  2014-10-21       Impact factor: 5.742

6.  High risk of lower urinary tract symptoms in patients with irritable bowel syndrome.

Authors:  F Zingone; P Iovino; A Santonicola; S Gallotta; C Ciacci
Journal:  Tech Coloproctol       Date:  2017-06-24       Impact factor: 3.781

Review 7.  Supraspinal Mechanisms of Intestinal Hypersensitivity.

Authors:  Olga A Lyubashina; Ivan B Sivachenko; Sergey S Panteleev
Journal:  Cell Mol Neurobiol       Date:  2020-10-08       Impact factor: 5.046

Review 8.  A functional subdivision within the somatosensory system and its implications for pain research.

Authors:  Qiufu Ma
Journal:  Neuron       Date:  2022-01-10       Impact factor: 17.173

9.  The Diagnosis of Chronic Pelvic Pain: How Can We Detect Urological Pain?

Authors:  Jung Ki Jo; Yong Tae Kim
Journal:  Int Neurourol J       Date:  2022-06-30       Impact factor: 3.038

10.  Visceral pressure stimulator for exploring hollow organ pain: a pilot study.

Authors:  Michael DeLong; Mauricio Gil-Silva; Veronica Minsu Hong; Olivia Babyok; Benedict J Kolber
Journal:  Biomed Eng Online       Date:  2021-03-25       Impact factor: 2.819

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.